The significance of the study:
Given that: (1) 15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in the US succumb to this disease; (3) obesity and type 2 diabetes are risk factor for the development of NAFLD; and (4) the global economic cost spent for NAFLD is enormous, there is an urgent need to find: (i) a way to decrease cholesterol deposition in liver; (ii) a cheaper alternative to the existing expensive drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, NAFLD.
Research findings to Therapeutic opportunity:
This study suggests a protein hormone-based therapy for NAFLD. Relaxin/Serelaxin, by increasing the expression of its target gene, it may suppress the expression of HMGCR (Fig.1). Thereby, it may: (1) decrease Triglycerides, free cholesterol and total cholesterol levels; (2) attenuate lipid deposition in the liver; and (3) inhibit progression to NAFLD (Fig. 1). Thus, pharmacological formulations encompassing “Relaxin/Serelaxin or its analogs, either alone or in combination with other drugs,” may be used to treat NAFLD.
Thus, by treating needy patients with Relaxin or its recombinant version (Serelaxin), one may prevent Non-alcoholic fatty liver disease (NAFLD). Together, this study suggests that (1) pharmacological formulations encompassing “Relaxin or its recombinant versions, either alone or in combination with other drugs,” may be used to decrease triglycerides, free cholesterol, and total cholesterol levels and treat NAFLD (fig. 2).
Given the mechanistic basis as to how relaxin may decrease triglycerides, free cholesterol, and total cholesterol levels, medical practitioners and cardiologists may consider treating their needy patients with Relaxin or its mimic such as Serelaxin [(recombinant human relaxin)-brand name: Reasanz)].
Details of the research findings:
Idea Proposed/Formulated (with experimental evidence) by:
Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed mechanistic information: How does Relaxin/Serelaxin decrease the expression of HMGCR to prevent progression of NAFLD?
# Research cooperation
For purchase and payment details, you may reach us at firstname.lastname@example.org
* Research cooperation
Web: http://genomediscovery.org or http://newbioideas.com
Citation: Boominathan, L., Revealing the unrevealed function of the reproductive hormone Relaxin in triglycerides/cholesterol reduction and in the treatment of Non-alcoholic fatty liver disease (NAFLD) : Relaxin, a protein hormone that facilitates labor and relaxes the uterine musculature, promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of NAFLD, via down-regulation of its target gene, 19/August/2018, 11.45 pm, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite, drop us a line at email@example.com